A comprehensive genomic and transcriptomic dataset of triple-negative breast cancers

被引:0
作者
Qingwang Chen
Yaqing Liu
Yuechen Gao
Ruolan Zhang
Wanwan Hou
Zehui Cao
Yi-Zhou Jiang
Yuanting Zheng
Leming Shi
Ding Ma
Jingcheng Yang
Zhi-Ming Shao
Ying Yu
机构
[1] Fudan University,State Key Laboratory of Genetic Engineering, School of Life Sciences and Human Phenome Institute
[2] Fudan University Shanghai Cancer Center,Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Precision Cancer Medicine Center
[3] Fudan University,Shanghai Cancer Hospital/Cancer Institute
[4] Fudan University,Fudan
[5] Greater Bay Area Institute of Precision Medicine,Gospel Joint Research Center for Precision Medicine
来源
Scientific Data | / 9卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Molecular subtyping of triple-negative breast cancer (TNBC) is essential for understanding the mechanisms and discovering actionable targets of this highly heterogeneous type of breast cancer. We previously performed a large single-center and multiomics study consisting of genomics, transcriptomics, and clinical information from 465 patients with primary TNBC. To facilitate reusing this unique dataset, we provided a detailed description of the dataset with special attention to data quality in this study. The multiomics data were generally of high quality, but a few sequencing data had quality issues and should be noted in subsequent data reuse. Furthermore, we reconduct data analyses with updated pipelines and the updated version of the human reference genome from hg19 to hg38. The updated profiles were in good concordance with those previously published in terms of gene quantification, variant calling, and copy number alteration. Additionally, we developed a user-friendly web-based database for convenient access and interactive exploration of the dataset. Our work will facilitate reusing the dataset, maximize the values of data and further accelerate cancer research.
引用
收藏
相关论文
共 64 条
  • [1] Dent R(2007)Triple-negative breast cancer: clinical features and patterns of recurrence Clin Cancer Res 13 4429-4434
  • [2] Siegel RL(2022)Cancer statistics, 2022 CA Cancer J Clin 72 7-33
  • [3] Miller KD(2018)Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis Ann Oncol 29 895-902
  • [4] Fuchs HE(2013)Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer J Clin Oncol 31 2586-2592
  • [5] Jemal A(2010)Triple-negative breast cancer N Engl J Med 363 1938-1948
  • [6] Bareche Y(2011)Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies J Clin Invest 121 2750-2767
  • [7] Baselga J(2015)Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer Clin Cancer Res 21 1688-1698
  • [8] Foulkes WD(2019)Molecular subtypes of triple-negative breast cancer in women of different race and ethnicity Oncotarget 10 198-208
  • [9] Smith IE(2016)Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer Breast Cancer Res 18 428-440 e425
  • [10] Reis-Filho JS(2019)Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies Cancer Cell 35 346-352